Rockwell MedicalFRA:RWM 30 EBIT per Share is €-1.00 as of Mar. 2026. GuruFocus rates FRA:RWM with a GF Score™ of 30/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, Rockwell Medical ranks better than 89.25% on this metric.
Rockwell Medical's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.29.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.00.
During the past 12 months, the average EBIT per Share Growth Rate of Rockwell Medical was -751.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 51.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Rockwell Medical's EBIT per Share or its related term are showing as below:
FRA:RWM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -104.5 Med: 17.5 Max: 59
Current: 51.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Rockwell Medical was 59.00% per year. The lowest was -104.50% per year. And the median was 17.50% per year.
FRA:RWM's 3-Year EBIT Growth Rate is ranked better than 89.25% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs FRA:RWM: 51.90
Rockwell Medical (FRA:RWM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Rockwell Medical EBIT per Share Related Terms
Rockwell Medical EBIT per Share Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (FRA:RWM) has a EBIT per Share of €-1.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #87 out of 809 companies in the Drug Manufacturers industry, placing it in the top 10.8%.
Is Rockwell Medical's EBIT per Share too high?
Rockwell Medical's current EBIT per Share is €-1.00. Based on the distribution chart, Rockwell Medical ranks #87 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's EBIT per Share compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #87 out of 809 companies for EBIT per Share. This places Rockwell Medical in the top 11% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current EBIT per Share is €-1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €5.25 — trading 483.3% above its estimated fair value. The current EBIT per Share is €-1.00. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current EBIT per Share is €-1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued.
The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90.
GuruFocus considers Rockwell Medical to be Significantly Overvalued.
Key valuation signals for FRA:RWM:
EBIT per Share: €-1.00
GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score
Get the complete analysis for FRA:RWM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWM has been successfully added to your 
